Pfizer has completion of its purchase of ReViral, a biopharmaceutical company.

The transaction expands Pfizer’s anti-infective pipeline and reinforces its commitment to developing medicines.

“This acquisition further demonstrates our commitment to advancing pioneering science – both through our in-house expertise and our work with leading, innovative companies – to deliver breakthroughs to patients suffering from serious infectious diseases,” said Mikael Dolsten, chief scientific officer of Pfizer. “We believe these therapeutic candidates – and the scientific expertise that has advanced their development – will complement our ongoing work to help combat RSV infections.”